申请人:Skw Trostberg Aktiengesellschaft
公开号:US05688947A1
公开(公告)日:1997-11-18
In order to produce a purine of the general formula (I), ##STR1## in which R.sup.1 and R.sup.2 can be the same or different and denote H, OH, SH, NH.sub.2, N-(di)-alkyl, halogen, O-alkyl, S-alkyl, alkyl or aryl and alkyl represents an aliphatic residue with 1 to 4 carbon atoms and aryl represents a phenyl residue which is substituted if desired by CH.sub.3, OH, NH.sub.2 or halogen, from the corresponding 4-amino-5-nitrosopyrimidine of formula (II), ##STR2## in which R.sup.1 and R.sup.2 have the above-mentioned meaning, the compound of formula (II) is reductively formylated in a solvent at a temperature of 80.degree. to 220.degree. C. in the presence of formic acid and a catalyst based on a noble metal and the 4-amino-5-formylaminopyrimidine formed as an intermediate is cyclized.
为了制备通式(I)的嘌呤,其中R.sup.1和R.sup.2可以相同或不同,表示H,OH,SH,NH.sub.2,N-(二)-烷基,卤素,O-烷基,S-烷基,烷基或芳基,烷基表示具有1至4个碳原子的脂肪残基,芳基表示苯基残基,如果需要则被CH.sub.3,OH,NH.sub.2或卤素取代,从相应的通式(II)的4-氨基-5-亚硝基嘧啶中,其中R.sup.1和R.sup.2具有上述含义,化合物的通式(II)在溶剂中在存在甲酸和基于贵金属的催化剂的情况下以80°C至220°C的温度还原酰化,形成的4-氨基-5-酰胺基嘧啶作为中间体被环化。